WideMed sleep monitor granted CE Mark

WideMed will expand its collaboration with GE Healthcare, which will market the Morpheus Hx software in Europe.

WideMed Ltd. (TASE:WDMD) has obtained EU CE Mark for its Morpheus Ox and Morpheus Hx cardio-sleep information systems, which will allow the company to market the products in Europe. Following the CE Mark certification, WideMed will expand its collaboration with GE Healthcare, which will market the Morpheus Hx in Europe.

WideMed cites a study by Frost and Sullivan, which estimates the European sleep industry market at $10 billion, and that 20 million Europeans suffer from chronic sleep disorders.

The Morpheus Hx includes software based on algorithms that can monitor sleep derived from data from standard sleep monitors manufactured by GE Healthcare. GE Healthcare has over $17 billion in annual turnover. The Morpheus Ox system uses a signal oxymeter to analyze sleep measures.

WideMed expects to launch sales of the Morpheus Ox in Europe in early 2011, provided that the company's suppliers meet delivery schedules.

WideMed's investors include Guidant Corporation, Platinum Neurone Ventures and Ascend Technology Ventures LP. The company's share price rose 16.2% by mid-afternoon to NIS 1.07, giving a market cap of NIS 17 million.

Published by Globes [online], Israel business news - www.globes-online.com - on September 7, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Biolight jumps on strong Zacks recommendation

Zacks cites the company for its technology, products, and meeting its targets.

VBL Therapeutics raises $40m in revived Nasdaq IPO

After the fiasco of the failed IPO in August, the drug development company scaled down the offering.

Assuta Hospital Gov't plans taxing private hospitals

The tax is one of the recommendations of the Economic Arrangments bill.

Erez Vigodman Teva boosted by European drug recommendations

Teva's share jumped 4% in Tel Aviv, after climbing 4.9% on Wall Street.

Partner/Orange Partner launches smartphone medical services

The new services includes prescriptions, hospital referrals, and confirmation of illness.

Reuven Krupik Clal Biotech unit PolyHeal nears licensing deal

PolyHeal has signed an MOU with a European drug company for an exclusive global license.

Nasdaq Galmed jumps on FDA hepatitis drug approval

The FDA awarded Fast Track Designation to aramchol for the treatment of Non-Alcoholic Steato-Hepatitis.

artificial sweeteners Weizmann Inst: Sweeteners cause diabetes, obesity

A study found that artificial sweeteners adversely affect intestinal bacteria.

BioCancell share jumps on positive cancer trial results

The clinical trials demonstrated safety and effectiveness of the treatment on high-risk bladder cancer patients.

Trendlines Group set for Toronto IPO

The technological incubators company is raising C$9 at a company value of C$80 million, after money.

Reuven Krupik Clal Biotech sues Hyperion for $200m

Clal Biotechnology alleges Hyperion made "rash and ill-considered" decisions in the Andromeda affair.

pharmaceuticals Clal Biotech: No evidence of misconduct by us

Clal Biotech says documents it was shown by Hyperion do not indicate it committed any misconduct regarding Andromeda.

Soroka Hospital  picture: Eyal Yitzhar Visiting Israel’s wounded at Soroka

Soroka Medical Center in Beersheva, the Israeli hospital closest to Gaza, bears the medical brunt of Operation Protective Edge.

Twitter Facebook Linkedin RSS Newsletters גלובס